Overseas Licensing Expands: UTop Pharma’s Semaglutide Injection Authorized in Over 90 Countries, Chinese GLP-1 Goes Global

Published: November 8, 2022
Source: Corporate News Center

UTop Pharma announced that its in-house developed Semaglutide injection has successfully secured licensing agreements covering more than 90 countries and regions through flexible commercial cooperation models. This milestone not only demonstrates the international competitiveness of the company’s product but also marks a significant step for Chinese GLP-1 drugs in achieving global commercialization.

1. Concrete Data: Global Coverage Demonstrates Competitiveness

With years of R&D accumulation and clinical validation, Semaglutide injection meets international standards in efficacy, safety, and production quality. The licensing agreements span key markets including North America, Europe, Southeast Asia, and the Middle East, and involve multiple international pharmaceutical partners.

“Licensing in over 90 countries and regions proves our product’s strong competitiveness and recognition in the global market.”
— Business Director, UTop Pharma

2. Diverse Cooperation Models: Flexible Approach to International Markets

UTop Pharma employs a variety of commercial collaboration models for overseas licensing, including:

• Out-Licensing: Partners obtain development and sales rights while sharing a portion of the profits;

• Profit-Sharing: Revenue is shared with partners in specific markets, reducing single-party market investment risks;

• Joint Promotion and Technical Support: The company provides manufacturing and quality support to ensure products meet local regulatory standards while protecting partner interests.

This flexible approach allows the company to quickly establish a cooperative network tailored to different market needs, enhancing the efficiency of global product deployment.

3. Market Response: Strong Interest and Broad Prospects

During the licensing process, UTop Pharma has engaged in in-depth discussions with multiple internationally renowned pharmaceutical companies, with positive indications across a broad geographic scope. The company continues to receive orders and market feedback from various regions, reflecting strong global interest and recognition of high-quality Chinese GLP-1 drugs.

“The global market shows strong interest in our GLP-1 products, which also validates the international recognition of China’s peptide drug R&D and manufacturing capabilities.”
— Founder, UTop Pharma

4. Strategic Significance: Chinese Peptide Drugs Go Global

This licensing milestone signifies a key advance in UTop Pharma’s global commercialization strategy:

• Further validates the company’s international competitiveness in GLP-1 drug R&D and manufacturing;

• Provides experience and a foundation for future overseas promotion of innovative peptide drugs;

• Elevates the global brand influence of high-end Chinese biologics, achieving a full-chain breakthrough from technological innovation to commercial value.

Conclusion

In 2022, UTop Pharma leveraged exceptional R&D capabilities and flexible commercial strategies to achieve another milestone on the global pharmaceutical stage. Moving forward, the company will continue to advance innovative drug development and international collaboration, delivering more globally competitive Chinese peptide products and high-quality treatment options to patients worldwide.

Issued by: Business Development Center
Editor: Corporate Branding Department
Date of Publication: November 8, 2022